Screening kit and method for diagnosing chronic immune dysfunction syndrome
AssigneeThe Regents of the University of California
InventorsJay A. Levy, Alan L. Landay
Life of this patent
Estimating the term…
Abstract
The subject invention permits diagnosis of chronic fatigue syndrome (CFS) by analyzing peripheral blood mononuclear cell subset populations and activation markers. A positive diagnosis for CFS is associated with an increase in the percentage of CD8+ cells showing CD38 or HLA-DR cell markers or a decrease in CD11b markers in CD8+ cells. The analysis is preferably performed using fluorochrome-labelled monoclonal antibodies specific for a determinant of the above subset cells and activation markers.
Claims5
A method for aiding in the diagnosis of chronic fatigue syndrome (CFS), comprising the steps of:
- (a) obtaining a sample of peripheral mononuclear cells from a host;
- (b) contacting the sample with an immunophenotypic panel comprising monoclonal antibodies for CD8.sup.+ antigens, CD11b antigens, CD38 antigens and HLA-DR antigens;
- and
- (c) allowing the antibodies to bind to an antigen and classifying said host as having CFS when said sample shows at least two of the following conditions:
- (i) a reduction in the percentage of CD8.sup.+ CD11b+ cells;
- or
- (ii) an increase in the percentage of CD8.sup.+ CD38+ cells, or
- (iii) an increase in the percentage of CD8.sup.+ HLA-DR cells as compared to percentages of cells having said markers obtained using control hosts not having chronic fatigue syndrome.
A kit for aiding in the diagnosis of chronic fatigue syndrome, comprising:
- an immunophenotypic panel of antibodies which includes monoclonal antibodies for CD8+ antigens, CD11b antigens, CD38 antigens and HLA-DR antigens, wherein each of the antibodies of the panel is labelled so as to be separately identifiable when used concurrently.
Dependencies are inferred from the claim text.